JAKKS Pacific Q2 2026: Revenue Grows 17% as International Sales Hit Record; Q3 Still Key

What happened

Second quarter 2026 net sales rose 17% year-over-year, with international achieving its highest first-half level in over a decade, providing early evidence that the 2025 revenue downturn was at least partially cyclical. The company reported these results in a July 23, 2026 press release, but the critical third quarter — which historically generates the vast majority of annual profit — remains ahead and will determine whether the recovery is sustained. The deep value report flagged that 2025's sharp sales decline could be structural, tied to tariffs and fewer theatrical tie-ins, but this quarter's improvement partly validates the report's 'POSSIBLE BUY' thesis if it continues into Q3. However, with cash still lower than year-end 2024 levels and minimum royalty guarantees of $79.7 million, the balance sheet remains stretched for a seasonal business that saw negative operating cash flow in the first nine months of 2025. The report's watch items (Q3 recovery, FCF sustainability, license renewals) are now partially addressed by Q2 strength, but a full thesis upgrade requires Q3 2026 to show normalized revenue and margins toward the $650-750 million annual range.

Implication

For investors, the Q2 2026 results tilt the odds slightly higher that 2025's revenue drop was a temporary slump rather than a structural decline, supporting a more constructive stance. The 17% sales growth, especially the international milestone, suggests JAKKS is regaining momentum with its licensed portfolio and retail partners, which could lead to improved full-year 2026 performance if Q3 delivers similar or better trends. However, the business remains highly seasonal with Q3 profit concentration, so caution is warranted until Q3 2026 data is released and shows revenue and EBITDA moving back toward 2023-2024 levels. The report's valuation case — trading below book with net cash — looks more compelling if the recovery persists, but the $79.7 million royalty guarantees and negative 2025 free cash flow remind us that liquidity risks remain. A prudent approach would be to wait for Q3 2026 earnings before upgrading from 'POSSIBLE BUY' to a firmer stance, but the improved Q2 is a necessary first step.

Thesis delta

The July 2026 Q2 print partially alleviates the report's key concern that 2025's revenue and EBITDA step-down might be structural, showing that top-line growth can resume when licensing and retail conditions improve. However, the report's caution about Q3 concentration and balance sheet pressures remains fully intact, and one quarter of 17% growth does not yet confirm a return to the $650-750 million revenue band. The thesis shifts from 'awaiting evidence of cyclical recovery' to 'early signals of cyclical recovery appear, but validation hinges on Q3 2026.'